Here's how a visiting venture capitalist explores Houston's startup ecosystem for the first time

a day in the life

Pat Matthews of Active Capital visited Houston with a collaboration with the HX Venture Fund. Photo courtesy of Active Capital

When Houston Exponential established the HX Venture Fund, the goal was to bring out-of-town capital and investors into the city of Houston. The fund of funds invests in a portfolio of venture capital funds with the hope that those funds find a way back into the Houston startup ecosystem.

After a little over a year, HXVF has invested in five funds: Boston-based .406 Ventures, Austin-based Next Coast Ventures, Boston-based OpenView Venture Partners, Washington D.C.-based Updata Partners, and Austin-based LiveOak Venture Partners.

The fund of funds is also regularly hosting those five funds — as well as a mix of potential portfolio fund members — in Houston for what the HXVF calls "immersion days" where the venture capitalists can meet local startups, innovation leaders, and even fellow investors that they could eventually co-invest with.

"The goals of these days are to have venture capitalists travel to Houston, meet with our entrepreneurs (and the startup development organizations like Station, Cannon and WeWork that support them), and provide both capital and expertise in company building to the tech companies," says Sandy Guitar Wallis, managing partner at HXVF. "The venture capitalists also meet with HX Venture Fund corporate LPs, who can be customers or acquirers of their portfolio companies."

Just this month alone, HXVF is hosting four funds — two from their portfolio and two that they haven't yet invested in. San Antonio-based Active Capital, which has raised a $21 million fund, is among the visiting VCs this month. The fund's founder, Pat Matthews, an entrepreneur turned venture capitalist, has shared his busiest day — February 5 — as well as his perspective on Houston innovation with InnovationMap.

A morning too busy for breakfast

After waking up at the Hotel Derek, Matthews starts his second day in Houston by taking a Lyft to the Greater Houston Partnership for what he believes to be a breakfast meeting with Wallis and Guillermo Borda of HXVF, but the group has too much to discuss that a meal falls by the wayside.

Before this trip, Matthews hasn't visited Houston in a professional capacity. While Active Capital is based just down I10 in San Antonio, the firm's investments are split almost in half by deals done in Texas versus the rest of the world. Active Capital focuses on B2B SaaS investments — usually leading — in seed or series A rounds.

Matthews has called Texas home for around a decade. He founded an email marketing startup in Virginia, which was acquired by San Antonio-based Rackspace. He relocated to join Rackspace and worked on growing the organization for six years before creating Active Capital.

Following the meeting — still unfed, Matthews meets up with Serafina Lalany from Houston Exponential to carpool to The Cannon on the west side of town.

Loading up on carbs and fireside chats

Matthews forgoes his usual carb aversion to eat slices of Domino's pizza at The Cannon before beginning his first of three fireside chats with Houston innovators. Patrick Schneidau, CEO of Truss, leads the conversation at The Cannon. (Schneidau is a board member of InnovationMap's.) After the chat, Matthews has a meeting with a startup before heading back into town.

With one fireside chat down, Matthews heads into his second one of the day at Station Houston with Joe Alapat, founder of Liongard. Matthews observes that each of the entrepreneurs who interviewed him had great questions, and seemed to be far along with their companies. Meanwhile, any of the people he met before or after the chat seemed to be at a much earlier stage in their startup journey.

The last fireside chat was hosted by Rakesh Agrawal of Snapstream at WeWork's Jones Building location. Matthews and Agrawal attempted to set up a Facebook livestream for the conversation, but an issue with the technology wouldn't allow for the stream.

An evening of good food and great mentorship

With meetings and fireside chats done, Matthews heads straight to a dinner with Blair Garrou, founder and managing director of Mercury Fund. The two venture capitalists dine at Eunice and split several appetizers and a bottle of wine while discussing their own recent investments and interests. Matthews, who met Garrou in 2014, thinks of him as a great mentor in venture capital.

Matthews headed back to the hotel after dinner and crashes hard after the long day. He would head back to San Antonio on a Vonlane bus — he gets a lot of work done on his trips — the next day.

What's next for Active Capital and Houston?

Matthews says he left Houston with an overall positive opinion of the city, and says it's similar to other Texas cities, aside from Austin, in its startup presence and capacity. While he assumed he'd meet energy and space startups, he realized Houston had a lot more going on than that.

"It definitely seemed like there was a lot of passion and a lot of hustle," Matthews says. "And it seems like the city is really working to support and cultivate that and keep it in Houston. I was inspired."

Throughout the visit, Matthews handed out his business card and some conversations have developed from those connections, he says. Another representative from Active Capital who is focused on sourcing deals with startups will visit next, and Matthews says he also thinks that he'll return to Houston to continue conversations he's been having, including some with other investors.

"I could definitely see doing deals in Houston," Matthews tells InnovationMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings